Concomitant use of XANAX with robust CYP3A inhibitors features a profound impact on the clearance of alprazolam, resulting in enhanced concentrations of alprazolam and enhanced possibility of adverse reactions [see Medical Pharmacology (twelve.three)]. Prevention or administration Past May, congr